Overview

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

Select 60 cases of women with breast cancer at clinical stage of T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500 mg/m2, 21day/cycle) as neoadjuvant chemotherapy. Finally the investigators assess the efficacy and safety of Albumin-bound Paclitaxel.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Tianjin Medical University

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel